drugset / Trial / NCT04305444
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will determine the efficacy of the triple combination therapy, DTRM-555, in patients with R/R CLL or R/R non-Hodgkin's lymphoma.
Timeline
- Start
- 2020-04-24
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Outcome
Outcome not reported
Stopped (Business): “Despite the efforts of our dedicated team and initial progress, we were unable to secure the necessary financial resources to continue the study. We appreciate the support and participation of all involved.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DTRMWXHS-12 | Unknown | 200 mg | Oral |
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 2 mg | Oral |